Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
UBS
Express Scripts
Deloitte
QuintilesIMS
Citi
Farmers Insurance
Accenture
Federal Trade Commission

Generated: December 13, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR EC-NAPROSYN

« Back to Dashboard

Clinical Trials for Ec-naprosyn

Trial ID Title Status Sponsor Phase Summary
NCT00153660 Celecoxib Versus Naproxen for Prevention of Recurrent Ulcer Bleeding in Arthritis Patients Unknown status Chinese University of Hong Kong Phase 3 The aim of this study is to compare a PPI (esomeprazole) plus a COX-2 inhibitor (celecoxib) with a PPI plus a nonselective NSAID (naproxen) in preventing recurrent ulcer bleeding in arthritis patients with a history of ulcer. The investigators hypothesized that among patients with a history of ulcer bleeding who receive prophylaxis with a PPI, celecoxib would be superior to naproxen for the prevention of recurrent ulcer bleeding irrespective of concomitant use of aspirin.
NCT00383487 A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer Terminated Novacea Phase 2 To determine whether, in this patient population, treatment with calcitriol and Naproxen is more effective in delaying the growth of prostate cancer than treatment with calcitriol alone as seen in historical controls.
NCT00383487 A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer Terminated Stanford University Phase 2 To determine whether, in this patient population, treatment with calcitriol and Naproxen is more effective in delaying the growth of prostate cancer than treatment with calcitriol alone as seen in historical controls.
NCT00527904 A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO) Completed POZEN Phase 3 This study uses an open-label design and will be conducted in approximately 60 sites aiming to enroll a total number of 200 subjects to ensure that at least 100 subjects will have 12 months exposure to PN400 (VIMOVO).
NCT00533247 Arthroplasty Inflammation Prophylaxis With Celecoxib Unknown status Zanbilowicz, Adam, DPM MS N/A This double blinded, placebo controlled, study seeks to determine the efficacy of preoperative anti-inflammatory therapy on the reduction of postoperative pain in knee arthroplasty surgery. Pre-emptive use of NSAIDS has demonstrated only modest reduction in post-operative pain in previous studies. However, the short duration of dosing in those studies did not capitalized on the anti-inflammatory properties of NSAIDS. Short-term use of NSAIDS only provides pain relief and does not address inflammation. Traditional NSAIDS cannot be used preoperatively due to platelet effects. Celecoxib, however, is both an analgesic and anti-inflammatory, but does not interfere with bleeding. It can therefore be safely used before surgery. This study hypothesizes that the use of celecoxib for seven days preoperatively reduces postoperative inflammation and consequently pain. A detailed Medline search has not identified any studies into the preoperative use of an NSAID at a dosing level that achieves anti-inflammatory effects.If effective in reducing postoperative pain, this research could lead to a new understanding of the role inflammation plays in orthopedic procedures and other elective procedures and thus improve patient outcomes in the future.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Ec-naprosyn

Condition Name

Condition Name for Ec-naprosyn
Intervention Trials
Healthy 4
Osteoarthritis 3
Surgery 2
Rib Fractures 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Ec-naprosyn
Intervention Trials
Stomach Ulcer 3
Migraine Disorders 3
Osteoarthritis 3
Pain, Postoperative 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Ec-naprosyn

Trials by Country

Trials by Country for Ec-naprosyn
Location Trials
United States 30
Sweden 4
Canada 4
United Kingdom 2
Egypt 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Ec-naprosyn
Location Trials
Texas 2
Illinois 2
Maryland 2
North Carolina 2
California 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Ec-naprosyn

Clinical Trial Phase

Clinical Trial Phase for Ec-naprosyn
Clinical Trial Phase Trials
Phase 4 2
Phase 3 2
Phase 2/Phase 3 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Ec-naprosyn
Clinical Trial Phase Trials
Completed 11
Recruiting 6
Unknown status 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Ec-naprosyn

Sponsor Name

Sponsor Name for Ec-naprosyn
Sponsor Trials
AstraZeneca 3
Oxford Pharmascience Ltd 2
Sahlgren´s University Hospital 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Ec-naprosyn
Sponsor Trials
Other 17
Industry 13
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Accenture
Cerilliant
QuintilesIMS
Queensland Health
AstraZeneca
Cipla
Fuji
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.